BACKGROUND: Critically ill neonates experience multiple stressors during hospitalization. Opioids are commonly prescribed to ameliorate their pain and stress. However, the enduring effects of stress and opioids are not understood. The kappa opioid system is important in the mediation of stress in adults, but little is known about its function in neonates. OBJECTIVES: To characterize kappa opioid receptor (KOR) distribution in the neonatal mouse brain and test whether neonatal exposure to morphine, stress, or both, change KOR signaling. METHODS: Five groups of wild-type C57BL/6 or prodynorphin (Pdyn) knockout mice were tested: (1) untreated control (dam-reared, no handling), (2) saline-injected control, (3) morphine-injected control, (4) stressed with saline injections and (5) stressed with morphine injections. Mice were treated from postnatal day 5 to postnatal day 9, after which their brains were immunolabeled with a phospho-specific KOR antibody (KOR-P), glial fibrillary acidic protein or glutamic acid decarboxylase. RESULTS: There were no effects of saline or morphine injection on KOR-P immunoreactivity. Neonatal stress increased KOR-P labeling in wild-type brains (p < 0.05), but not in Pdyn(-/-) animals. Mice exposed to stress and morphine showed region-specific increases in KOR-P immunoreactivity from 38 to 500% (p < 0.05 to p < 0.001), with marked gliosis. In stressed morphine-treated Pdyn(-/-) animals, KOR-P immunoreactivity was absent, but gliosis increased compared to wild-type animals. CONCLUSIONS: Neonatal stress increases KOR activation via the dynorphin system. Neonatal stress plus morphine treatment further increased this response and also resulted in hippocampal gliosis. Enhanced gliosis noted in Pdyn(-/-) animals suggests that the endogenous dynorphin may play a role in downregulating this inflammatory response. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: Critically ill neonates experience multiple stressors during hospitalization. Opioids are commonly prescribed to ameliorate their pain and stress. However, the enduring effects of stress and opioids are not understood. The kappa opioid system is important in the mediation of stress in adults, but little is known about its function in neonates. OBJECTIVES: To characterize kappa opioid receptor (KOR) distribution in the neonatal mouse brain and test whether neonatal exposure to morphine, stress, or both, change KOR signaling. METHODS: Five groups of wild-type C57BL/6 or prodynorphin (Pdyn) knockout mice were tested: (1) untreated control (dam-reared, no handling), (2) saline-injected control, (3) morphine-injected control, (4) stressed with saline injections and (5) stressed with morphine injections. Mice were treated from postnatal day 5 to postnatal day 9, after which their brains were immunolabeled with a phospho-specific KOR antibody (KOR-P), glial fibrillary acidic protein or glutamic acid decarboxylase. RESULTS: There were no effects of saline or morphine injection on KOR-P immunoreactivity. Neonatal stress increased KOR-P labeling in wild-type brains (p < 0.05), but not in Pdyn(-/-) animals. Mice exposed to stress and morphine showed region-specific increases in KOR-P immunoreactivity from 38 to 500% (p < 0.05 to p < 0.001), with marked gliosis. In stressed morphine-treated Pdyn(-/-) animals, KOR-P immunoreactivity was absent, but gliosis increased compared to wild-type animals. CONCLUSIONS:Neonatal stress increases KOR activation via the dynorphin system. Neonatal stress plus morphine treatment further increased this response and also resulted in hippocampal gliosis. Enhanced gliosis noted in Pdyn(-/-) animals suggests that the endogenous dynorphin may play a role in downregulating this inflammatory response. Copyright 2009 S. Karger AG, Basel.
Authors: A Stiene-Martin; P E Knapp; K Martin; J A Gurwell; S Ryan; S R Thornton; F L Smith; K F Hauser Journal: Glia Date: 2001-10 Impact factor: 7.452
Authors: Jared F Boasen; Ronald J McPherson; Sarah L Hays; Sandra E Juul; Christine A Gleason Journal: Neonatology Date: 2008-10-27 Impact factor: 4.035
Authors: K J S Anand; R Whit Hall; Nirmala Desai; Barbara Shephard; Lena L Bergqvist; Thomas E Young; Elaine M Boyle; Ricardo Carbajal; Vinod K Bhutani; Mary Beth Moore; Shari S Kronsberg; Bruce A Barton Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Sinno H P Simons; Monique van Dijk; Richard A van Lingen; Daniella Roofthooft; Hugo J Duivenvoorden; Niesje Jongeneel; Carin Bunkers; Enna Smink; K J S Anand; John N van den Anker; Dick Tibboel Journal: JAMA Date: 2003-11-12 Impact factor: 56.272
Authors: Sarah L Hays; Ronald J McPherson; Sandra E Juul; Gerard Wallace; Abigail G Schindler; Charles Chavkin; Christine A Gleason Journal: Behav Brain Res Date: 2011-10-28 Impact factor: 3.332
Authors: Christopher M Traudt; Ivan Tkac; Kathleen M Ennis; Leah M Sutton; Daniel M Mammel; Raghavendra Rao Journal: J Neurosci Res Date: 2011-10-04 Impact factor: 4.164
Authors: J R Rozisky; G Laste; I C de Macedo; V S Santos; R Krolow; C Noschang; C Vanzella; K Bertoldi; G A Lovatel; I C C de Souza; I R Siqueira; C Dalmaz; W Caumo; I L S Torres Journal: Neurochem Res Date: 2012-12-09 Impact factor: 3.996
Authors: Joshua D Gross; Shane W Kaski; Karl T Schmidt; Elizabeth S Cogan; Kristen M Boyt; Kim Wix; Adam B Schroer; Zoe A McElligott; David P Siderovski; Vincent Setola Journal: Neuropsychopharmacology Date: 2019-05-29 Impact factor: 7.853
Authors: Ryan M McAdams; Ronald J McPherson; Richard P Beyer; Theo K Bammler; Frederico M Farin; Sandra E Juul Journal: PLoS One Date: 2015-04-06 Impact factor: 3.240